Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Body Fluids as a Source of Diagnostic Biomarkers: Prostate

Body Fluids as a Source of Diagnostic Biomarkers: Prostate

67
Semmes, JohnEastern Virginia Medical School
m/z pattern
Prospective
Proteomics
Prostate and Urologic Cancers Research Group

Recent advances in high-throughput protein expression profiling of bodily fluids has generated great enthusiasm and hope for this approach as a potent diagnostic tool. At the center of these efforts is the application of SELDI-TOF-MS and artificial intelligence algorithms by the EDRN BDL site at Eastern Virginia Medical School and the DMCC respectively. When the expression profiling process was applied to sera from individuals with prostate cancer (N=197), BPH (N=92) or from otherwise healthy donors (N=97) we achieved an overall misclassification rate of <10%. The sensitivity was 83% and the specificity was 100% with an overall positive predictive value of 91.15%. This result is a significant improvement over PSA which presents as only 25% specificity and >90% sensitivity. Since this represents a noticeable improvement in current clinical approach we are proposing to embark upon a validation process. The described studies are designed to address validation issues and include three phases. Phase 1; Synchronization of SELDI Output within the EDRN-Prostate-SELDI Investigational Collaboration (EPSIC); addressing portability (A) Synchronize SELDI instrumentation and robotic sample processing across the EPSIC using pooled serum(QC); (B) Establish the portability and reproducibility of the SELDI protein profiling approach within the EPSIC using normal and prostate cancer patient’s serum from a single site; (C) Establish robustness of the approach toward geographic, sample collection and processing differences within EPSIC using case and control serum from five different sites. Phase 2; Population Validation Establish geographic variability and robustness in a large cross-sectional study among different sample population. Phase 3; Clinical Validation; validate the serum protein expression profiling coupled with a learning algorithm as a means for early detection of prostate cancer using longitudinal PCPT samples. We have assembled a cohesive multi-institutional team for completing these studies in a timely and efficient manner. The team consists of five EDRN laboratories, DMCC and CBI and the proposed budget reflects the total involvement.

The specific aims are elaborated in the Validation protocol submitted earlier.
SELDI-TOF, MALDI-TOF/TOF, SELDI-QStar
The three article that emerged from this study have been well referenced and represent the new standard for validation of high-throughput proteomics data. The last two mansucripts were published back to back in Clinical Chemistry with three invited editorials to comment on the research.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement